Anthropic acquires one-person startup Mithril Medicine for drug discovery Anthropic

Anthropic acquired Mithril Medicine, a one-person biotechnology startup using Claude AI agents to develop treatments for rare pediatric genetic diseases.

Founder Cody Tranbarger used Claude to coordinate experimental workflows across 11 partner laboratories, advancing bispecific antibody candidates for muscular dystrophy from concept to in vivo mouse data in less than 18 months.

What it is

• One-person AI biotech acquisition. Mithril Medicine operated with a single full-time employee, relying on Claude agents to organize contracts, logistics, data analysis, and laboratory handoffs.
• Targeted disease indications. The company focuses on two rare genetic disorders: LAMA2-related congenital muscular dystrophy (LAMA2-CMD) and alpha-dystroglycanopathy (αDG).
• Bispecific antibody design. Mithril's drug candidates use bispecific antibodies to restore the critical mechanical connection between laminin and dystroglycan in muscle cells.
• Anthropic internal drug programs. Mithril's research represents Anthropic's first in-house drug development programs, with Tranbarger now leading internal biological pipelines toward targeted clinical trials by 2028 and 2029.
• Accelerated experimental cycles. Developing a complete research thesis, molecule design plan, and experimental strategy took two to three days with Claude, compared to one to two months traditionally.

Development roadmap

Sources

• Anthropic Research: Early Progress on Accelerating Drug Development with Claude